Home » Stocks » ORGO

Organogenesis Holdings, Inc. (ORGO)

Stock Price: $17.18 USD -0.74 (-4.13%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $17.84 +0.66 (3.84%) May 12, 7:56 PM
Market Cap 2.30B
Revenue (ttm) 379.12M
Net Income (ttm) 44.21M
Shares Out 127.87M
EPS (ttm) 0.16
PE Ratio 107.38
Forward PE 153.85
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $17.18
Previous Close $17.92
Change ($) -0.74
Change (%) -4.13%
Day's Open 17.80
Day's Range 16.86 - 18.04
Day's Volume 665,166
52-Week Range 3.01 - 24.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Organogenesis (ORGO) delivered earnings and revenue surprises of 275.00% and 18.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First...

2 days ago - GlobeNewsWire

Shares of Organogenesis Holdings (NASDAQ:ORGO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 143.75% year over year to $0.07, which b...

2 days ago - Benzinga

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of prod...

2 days ago - GlobeNewsWire

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of prod...

2 days ago - GlobeNewsWire

Organogenesis Holdings (NASDAQ:ORGO) releases its next round of earnings this Monday, May 10. Here is Benzinga's essential guide to Organogenesis Holdings's Q1 earnings report.

5 days ago - Benzinga

CANTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of produ...

6 days ago - GlobeNewsWire

CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

1 month ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

1 month ago - Zacks Investment Research

Avista Healthcare saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 92 the day before. The post Avista Healthcare Earns Membership In 95-Plus Composite Rating Club appeared first on In...

1 month ago - Investors Business Daily

Organogenesis (ORGO) delivered earnings and revenue surprises of 25.00% and 1.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Organogenesis Holdings (NASDAQ:ORGO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 500.00% over the past year to $0.16, which be...

1 month ago - Benzinga

CANTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

1 month ago - GlobeNewsWire

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

If the insiders are selling, they may think their shares are overvalued. These seven stocks have recent insider trading sell signals.

Other stocks mentioned: AMKR, ENVA, EWBC, ONEW, PXLW, RFP
2 months ago - InvestorPlace

CANTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

2 months ago - GlobeNewsWire

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ONCT, RDUS, TPTX, USNA
3 months ago - Zacks Investment Research

CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

3 months ago - GlobeNewsWire

CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

3 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

3 months ago - Zacks Investment Research

ORGANOGENESIS (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

3 months ago - Zacks Investment Research

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: MRO, WPRT, BIOL, KERN
3 months ago - 24/7 Wall Street

The company announced its preliminary fourth-quarter financial results.

3 months ago - The Motley Fool

CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of prod...

3 months ago - GlobeNewsWire

These are the stocks posting the largest moves after the bell on Wednesday.

Other stocks mentioned: ETH, JWN
3 months ago - CNBC

CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

3 months ago - GlobeNewsWire

FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis

4 months ago - GlobeNewsWire

New strain of coronavirus, growing demand for digitization and past record indicate that the Nasdaq can win in 2021 too after its best year since 2009.

Other stocks mentioned: AEIS, AOSL, COHU, UCTT
4 months ago - Zacks Investment Research

CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

4 months ago - GlobeNewsWire

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

5 months ago - Zacks Investment Research

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, BH, GSKY, GTHX, KROS, REYN, WTRH
5 months ago - Benzinga

Organogenesis is a revenue-generating regenerative medicines company with a long pipeline. The company has decades of operating history behind it.

5 months ago - Seeking Alpha

CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

5 months ago - GlobeNewsWire

CANTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

6 months ago - GlobeNewsWire

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

6 months ago - GlobeNewsWire

CANTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of prod...

6 months ago - GlobeNewsWire

The company released preliminary third-quarter results.

6 months ago - The Motley Fool

CANTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

6 months ago - GlobeNewsWire

CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

7 months ago - GlobeNewsWire

CANTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

8 months ago - GlobeNewsWire

CANTON, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

8 months ago - GlobeNewsWire

Organogenesis Holdings, Inc. (ORGO) CEO Gary Gillheeney on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Organogenesis (ORGO) delivered earnings and revenue surprises of 58.33% and 0.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CANTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

9 months ago - GlobeNewsWire

Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of ...

9 months ago - GlobeNewsWire

CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

9 months ago - GlobeNewsWire

Organogenesis Holdings, Inc. (ORGO) CEO Gary Gillheeney on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 0.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ul... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1985
Stock Exchange
NASDAQ
Ticker Symbol
ORGO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ORGO stock is "Strong Buy." The 12-month stock price forecast is 26.25, which is an increase of 52.79% from the latest price.

Price Target
$26.25
(52.79% upside)
Analyst Consensus: Strong Buy